Description:

HERCURA (Trastuzumab) is a humanized monoclonal antibody that specifically targets the HER2/neu receptor (human epidermal growth factor receptor 2). It is used in the treatment of HER2-positive breast and gastric cancers. Overexpression of HER2 is associated with aggressive tumor growth and poor prognosis; HERCURA works by selectively binding to this receptor, inhibiting proliferation and inducing antibody-dependent cell-mediated cytotoxicity.
Trastuzumab binds with high affinity to the extracellular domain of the HER2 protein. This blocks HER2 receptor activation, downregulates HER2 signalling, and mediates the destruction of cancer cells via immune mechanisms such as:

• Antibody-dependent cell-mediated cytotoxicity (ADCC)
• Inhibition of intracellular signalling pathways that promote cell division and survival